Product Information
DABIGATRAN ETEXILATE 110 MG CP is a generic product labeled by Ascend Laboratories, LLC, priced at $0.9460 per EA under NDC 67877062460. Its NADAC has been published 38 times since Dec 3, 2025.
FDA first approved this application on Mar 11, 2020. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
110 mg/1
Manufacturer
Ascend Laboratories, LLCNDC
67877062460
Classification
Generic
Dosage Form
CAPSULE, COATED PELLETS
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
DABIGATRAN ETEXILATE MESYLATEApproval Type
Generic (ANDA)
FDA Application
ANDA208040FDA Approved
3/11/2020
TE Code
AB
On Market Since
9/12/2025
Pharmacological Classes
Price Statistics
The NADAC for DABIGATRAN ETEXILATE 110 MG CP has been published 38 times since Dec 3, 2025, and over the history we have for it it has declined 41.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.9460 per EA |
|---|---|
| All-time high | $1.6053 (Dec 10, 2025) |
| All-time low | $0.9196 (May 20, 2026) |
| 52-week high | $1.6053 |
| 52-week low | $0.9196 |
| Median price | $1.0186 |
| Average price | $1.0972 |
| Largest weekly change | -12.4% (Dec 17, 2025) |
| Weeks tracked | 38 |
| Tracking since | Dec 3, 2025 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of DABIGATRAN ETEXILATE 110 MG CP?
The current National Average Drug Acquisition Cost (NADAC) for DABIGATRAN ETEXILATE 110 MG CP, manufactured by Ascend Laboratories, LLC, is $0.9460 per EA (NDC 67877062460), effective Aug 19, 2026.
How has the price of DABIGATRAN ETEXILATE 110 MG CP changed over time?
Over the history we have for it, the NADAC for DABIGATRAN ETEXILATE 110 MG CP has declined 41.1%. It has been tracked across 38 weekly CMS publications since Dec 3, 2025.
What are the highest and lowest recorded NADAC prices for DABIGATRAN ETEXILATE 110 MG CP?
Since Dec 3, 2025, the NADAC for DABIGATRAN ETEXILATE 110 MG CP has ranged from a low of $0.9196 (May 20, 2026) to a high of $1.6053 (Dec 10, 2025), with a median of $1.0186 per EA.
Are there cheaper alternatives to DABIGATRAN ETEXILATE 110 MG CP?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as DABIGATRAN ETEXILATE 110 MG CP in a comparable dosage form, but none are currently priced below it.
Who manufactures DABIGATRAN ETEXILATE 110 MG CP?
DABIGATRAN ETEXILATE 110 MG CP (NDC 67877062460) is labeled by Ascend Laboratories, LLC, and CMS classifies it as a generic product.